Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
205.438.01010 Boehringer Ingelheim Investigational Site
mi
from
Manchester, NH
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
205.438.01010 Boehringer Ingelheim Investigational Site
mi
from
Manchester, NH
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
205.452.01293 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, NY
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
205.452.01293 Boehringer Ingelheim Investigational Site
mi
from
Syracuse, NY
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
1199.15.10029 Boehringer Ingelheim Investigational Site
mi
from
Cleveland, OH
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
1199.15.10029 Boehringer Ingelheim Investigational Site
mi
from
Cleveland, OH
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Oklahoma City, OK
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
1199.14.1088 Boehringer Ingelheim Investigational Site
mi
from
Milwaukee, WI
Tiotropium Bromide in Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Parallel-group Trial to Confirm the Efficacy After 12 Weeks and the Safety of Tiotropium 5 Mcg Administered Once Daily Via the Respimat® Device in Patients With Cystic Fibrosis.
Status: Archived
Updated: 1/1/1970
1199.14.1088 Boehringer Ingelheim Investigational Site
mi
from
Milwaukee, WI
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF
Status: Archived
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF
Status: Archived
Updated: 1/1/1970
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?
Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study
Status: Archived
Univeristy of Wisconsin Hospital and Clinics
mi
from
Madison, WI
DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?
Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea? DREAM-A Pilot Study
Status: Archived
Updated: 1/1/1970
Univeristy of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years
Status: Archived
Spectrum Health Hospital
mi
from
Grand Rapids, MI
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years
Status: Archived
Updated: 1/1/1970
Spectrum Health Hospital
mi
from
Grand Rapids, MI
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome
Status: Archived
OU Medical Center
mi
from
Oklahoma City, OK
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome
Status: Archived
Updated: 1/1/1970
OU Medical Center
mi
from
Oklahoma City, OK
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome
Status: Archived
Veterans Affairs Medical Center
mi
from
Oklahoma City, OK
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS)
Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center
mi
from
Oklahoma City, OK
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Baltimore, MD
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Baltimore, MD
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Ayer, MA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ayer, MA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Grand Island, NE
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Grand Island, NE
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Oklahoma City, OK
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Oklahoma City, OK
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Anderson, SC
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Anderson, SC
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
University of Alabama at Birmingham
mi
from
Birmingham, AL
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
mi
from
Birmingham, AL
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
University of Chicago
mi
from
Chicago, IL
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
Indiana Univeristy School of Medicine
mi
from
Indianapolis, IN
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
University of Louisville Hospital
mi
from
Louisville, KY
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
University of Louisville Hospital
mi
from
Louisville, KY
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Ohio State University
mi
from
Columbus, OH
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase One, Open Label, Multi-Dose Study to Evaluate the Safety, Tolerability, and Biologic Effects of Three Doses of IW001 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Providence Western Washington Oncology
mi
from
Lacey, WA
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Providence Western Washington Oncology
mi
from
Lacey, WA
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Miami, FL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Miami, FL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Ann Arbor, MI
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Ann Arbor, MI
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Rochester, MN
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Rochester, MN
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
University of Chicago
mi
from
Chicago, IL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Chesapeake Clinical Research, Inc
mi
from
Baltimore, MD
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Chesapeake Clinical Research, Inc
mi
from
Baltimore, MD
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
High Point, NC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
High Point, NC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Cincinatti, OH
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Cincinatti, OH
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis
mi
from
Portland, OR
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis
mi
from
Portland, OR
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Mt. Pleasant, SC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Knoxville, TN
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Knoxville, TN
DeVilbiss AutoAdjust With SmartFlex Comparative Study
A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; "AutoAdjust With SmartFlex Study"
Status: Archived
Sleep Medicine Associates of Texas
mi
from
Dallas, TX
DeVilbiss AutoAdjust With SmartFlex Comparative Study
A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; "AutoAdjust With SmartFlex Study"
Status: Archived
Updated: 1/1/1970
Sleep Medicine Associates of Texas
mi
from
Dallas, TX
DeVilbiss AutoAdjust With SmartFlex Comparative Study
A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; "AutoAdjust With SmartFlex Study"
Status: Archived
Sleep Therapy and Research Center
mi
from
San Antonio, TX
DeVilbiss AutoAdjust With SmartFlex Comparative Study
A Multi Center, Prospective, Randomized, Double Blind, Crossover Study to Compare the DeVilbiss AutoAdjust With and Without the Smartflex Device Modification; "AutoAdjust With SmartFlex Study"
Status: Archived
Updated: 1/1/1970
Sleep Therapy and Research Center
mi
from
San Antonio, TX
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis
A Phase II Randomized, Double Blind, Placebo-controlled, Trial of Combination Antifungal Therapy (Voriconazole Plus Micafungin vs. Voriconazole Plus Placebo Equivalent) in the Treatment of Invasive Aspergillosis (IA) in Patients With Hematological Cancer
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
University of Florida Gainesville
mi
from
Gainesville, FL
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Updated: 1/1/1970
University of Florida Gainesville
mi
from
Gainesville, FL
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
University of Miami Hospital
mi
from
Miami, FL
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
mi
from
Miami, FL
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Temple University
mi
from
Philadelphia, PA
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Updated: 1/1/1970
Temple University
mi
from
Philadelphia, PA
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
A Randomized Double-blind Crossover Study to Assess the Safety and Pharmacokinetics of Two Different Doses of Weekly Intravenous Administration of Alpha1-Proteinase Inhibitor (Human) Prolastin-C in Subjects With Alpha1-Antitrypsin Deficiency
Status: Archived
Updated: 1/1/1970
The University of Texas Health Science Center at San Antonio, Medical Arts and Research Center
mi
from
San Antonio, TX
Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.
Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.
Status: Archived
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.
Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients at the CF Center at SUNY Upstate Medical University, Syracuse, NY.
Status: Archived
Updated: 1/1/1970
State University of New York - Erie Country Medical Center
mi
from
Buffalo, NY
Bariatric Surgery and Obstructive Sleep Apnea
Effects of Bariatric Surgery on Obstructive Sleep Apnea
Status: Archived
Summa Health System
mi
from
Akron, OH
Bariatric Surgery and Obstructive Sleep Apnea
Effects of Bariatric Surgery on Obstructive Sleep Apnea
Status: Archived
Updated: 1/1/1970
Summa Health System
mi
from
Akron, OH